stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
51.90
3.44
+7.10%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) EPS (diluted)
MBX Biosciences, Inc.'s EPS (diluted) for fiscal 2025 was −$2.38, compared with −$5.82 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$2.41. EPS (diluted) has risen for 3 consecutive fiscal years. MBX Biosciences, Inc. ranks 345th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$2.38 | — |
| FY2024 | −$5.82 | — |
| FY2023 | −$31.96 | — |
| FY2022 | −$39.18 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.78 | — |
| Mar 2026 | −$0.51 | — |
| Dec 2025 | −$0.49 | — |
| Sep 2025 | −$0.63 | — |
| 7 more quarters | Free account |
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ADMA ADMA Biologics Inc compare | $0.77 |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$0.90 |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$1.69 |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$1.71 |
| XNCR Xencor, Inc. compare | −$2.17 |
| MBX MBX Biosciences, Inc. | −$2.41 |
| PHVS Pharvaris N.V. compare | −$3.05 |
| RCUS Arcus Biosciences, Inc. compare | −$3.63 |
| CLDX Celldex Therapeutics, Inc. compare | −$4.35 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item